Cancer Immunotherapy: Dendritic Cell Vaccines (DC Vaccines) and Chimeric Antigen Receptor T-Cell Therapy (CAR T-Cell Therapy)

01   Core Expertise

We provide integrated assessment of dendritic cell antigen presentation and genetically engineered T-cell therapies, tailoring immunotherapy strategies to tumor characteristics, treatment indications, and individual risk profiles while balancing potential clinical benefits with careful safety monitoring.

02   Key Features

For cancers that have recurred or have responded poorly to standard treatment, we assess whether cellular immunotherapy is appropriate, as well as its potential benefits and risks. Dendritic cell (DC) vaccines present tumor antigens to activate the patient’s own immune response, while CAR T-cell therapy modifies T cells so they can recognize specific tumor antigens. These therapies differ in both their mechanisms and the situations in which they may be used. Care is coordinated across pathology and molecular testing, treatment selection, cell preparation and infusion, response follow-up, and toxicity monitoring. Patients receive care from a multidisciplinary team that includes specialists in oncology, hematology, and cellular therapy, as well as pharmacists and nursing staff.

03   Clinical Outcomes

These are Phase I and individual-participant observations described in the department's materials; they should not be interpreted as an overall response rate or evidence of routine treatment approval.

04   Selected Research Publications

05   International Accreditations and Awards